These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 24788096)

  • 1. Programmable transdermal clonidine delivery through voltage-gated carbon nanotube membranes.
    Strasinger C; Paudel KS; Wu J; Hammell D; Pinninti RR; Hinds BJ; Stinchcomb A
    J Pharm Sci; 2014 Jun; 103(6):1829-38. PubMed ID: 24788096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carbon Nanotube Membranes for use in the Transdermal Treatment of Nicotine Addiction and Opioid Withdrawal Symptoms.
    Strasinger CL; Scheff NN; Wu J; Hinds BJ; Stinchcomb AL
    Subst Abuse; 2009 Mar; 3():31-39. PubMed ID: 20582253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Programmable transdermal drug delivery of nicotine using carbon nanotube membranes.
    Wu J; Paudel KS; Strasinger C; Hammell D; Stinchcomb AL; Hinds BJ
    Proc Natl Acad Sci U S A; 2010 Jun; 107(26):11698-702. PubMed ID: 20547880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A preclinical evaluation of a programmable CNT membrane device for transdermal nicotine delivery in hairless Guinea pigs.
    Gulati GK; Berger LR; Hinds BJ
    J Control Release; 2019 Jan; 293():135-143. PubMed ID: 29990525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clonidine for Sedation and Analgesia and Withdrawal in Critically Ill Infants and Children.
    Capino AC; Miller JL; Johnson PN
    Pharmacotherapy; 2016 Dec; 36(12):1290-1299. PubMed ID: 27779775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Programmable carbon nanotube membrane-based transdermal nicotine delivery with microdialysis validation assay.
    Gulati GK; Chen T; Hinds BJ
    Nanomedicine; 2017 Jan; 13(1):1-9. PubMed ID: 27438911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transdermal clonidine for mitigating posttraumaticdisorder in an ad stress olescent.
    Ye L; Shipley E; Lippmann S
    Am J Health Syst Pharm; 2019 Apr; 76(8):487-488. PubMed ID: 31361867
    [No Abstract]   [Full Text] [Related]  

  • 8. Clonidine transdermal patches for use in outpatient opiate withdrawal.
    Spencer L; Gregory M
    J Subst Abuse Treat; 1989; 6(2):113-7. PubMed ID: 2664204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of voltage gated transdermal drug delivery platform to impose synergistic enhancement in skin permeation using electroporation and gold nanoparticle.
    Anirudhan TS; Nair SS
    Mater Sci Eng C Mater Biol Appl; 2019 Sep; 102():437-446. PubMed ID: 31147014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpha Alert: Utilization of Transdermal Clonidine for Refractory Agitation.
    Grable S; Houchard G; Rossfeld Z
    J Pain Palliat Care Pharmacother; 2024 Jun; 38(2):149-152. PubMed ID: 38484176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of high-dose enteral, intravenous, and transdermal clonidine for the acute management of severe intractable childhood dystonia and status dystonicus: An illustrative case-series.
    Nakou V; Williamson K; Arichi T; Lumsden DE; Tomlin S; Kaminska M; Lin JP
    Eur J Paediatr Neurol; 2017 Nov; 21(6):823-832. PubMed ID: 28844551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacokinetics of clonidine.
    Lowenthal DT; Matzek KM; MacGregor TR
    Clin Pharmacokinet; 1988 May; 14(5):287-310. PubMed ID: 3293868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transdermal clonidine: therapeutic considerations.
    Sica DA; Grubbs R
    J Clin Hypertens (Greenwich); 2005 Sep; 7(9):558-62. PubMed ID: 16227779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of opiate withdrawal symptoms with use of clonidine in a county jail.
    Fresquez-Chavez KR; Fogger S
    J Correct Health Care; 2015 Jan; 21(1):27-34. PubMed ID: 25431436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transdermal clonidine reduced some withdrawal symptoms but did not increase smoking cessation.
    Prochazka AV; Petty TL; Nett L; Silvers GW; Sachs DP; Rennard SI; Daughton DM; Grimm RH; Heim C
    Arch Intern Med; 1992 Oct; 152(10):2065-9. PubMed ID: 1417380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alpha 2-agonist versus alpha 1-antagonist in mild-to-moderate hypertension: comparison of transdermal clonidine and terazosin monotherapies.
    Harris SI; Alvarez C
    Am J Ther; 1997 Jan; 4(1):9-15. PubMed ID: 10423584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transdermal clonidine. A preliminary review of its pharmacodynamic properties and therapeutic efficacy.
    Langley MS; Heel RC
    Drugs; 1988 Feb; 35(2):123-42. PubMed ID: 3281820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Electrically controlled nicotine delivery through Carbon nanotube membranes via electrochemical oxidation and nanofluidically enhanced electroosmotic flow.
    Gulati GK; Hinds BJ
    Biomed Microdevices; 2021 Sep; 23(4):48. PubMed ID: 34562167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spontaneous right coronary artery dissection possibly associated with clonidine transdermal patch.
    Cilingiroğlu M; Rahman S; Helmy T; Seshiah P
    Turk Kardiyol Dern Ars; 2011 Apr; 39(3):224-7. PubMed ID: 21532299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical experience with rate-controlled delivery of antihypertensive therapy by a transdermal system.
    Weber MA; Drayer JI
    Am Heart J; 1984 Jul; 108(1):231-6. PubMed ID: 6375331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.